Media headlines about Fortress Biotech (NASDAQ:FBIO) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fortress Biotech earned a news impact score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.7197441739183 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Fortress Biotech, Inc. (FBIO) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- ETFs with exposure to Fortress Biotech, Inc. : October 30, 2017 (finance.yahoo.com)
- Impax Laboratories, Inc. (IPXL) registers a price change of -2.21% while Fortress Biotech, Inc. (FBIO) finishes with … – Stocks Gallery (stocksgallery.com)
- Signal Watch: Ultimate Oscillator Seen Under 40 for Fortress Biotech Inc (FBIO) – Lockport Press (lockportpress.com)
A number of equities research analysts have recently weighed in on the company. ValuEngine cut Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. HC Wainwright set a $11.00 price objective on Fortress Biotech and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Rodman & Renshaw assumed coverage on Fortress Biotech in a research note on Tuesday, July 11th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, FBR & Co reaffirmed a “buy” rating on shares of Fortress Biotech in a research note on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.00.
Shares of Fortress Biotech (FBIO) traded down 0.80% during midday trading on Tuesday, hitting $3.74. The stock had a trading volume of 100,415 shares. Fortress Biotech has a 12-month low of $1.88 and a 12-month high of $5.13. The stock’s market cap is $188.97 million. The stock has a 50-day moving average price of $4.41 and a 200-day moving average price of $4.29.
Fortress Biotech Company Profile
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
What are top analysts saying about Fortress Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fortress Biotech Inc. and related companies.